Andrew Snyder has been on the editorial team of a bunch of different Agora-affiliated newsletters over the years, and is now helming his own little offshoot called Manward Press — a publishing imprint that aims to helm men reach “true fulfillment” by focusing on “Liberty, Know-how and connections” … though, of course, to sell newsletters […]
Lots and lots and lots of you have been asking me about the big “cancer presentation” that the Stansberry folks made last night, which apparently was a combination of Dr. David Eifrig’s medical advice and forecasting and Dave Lashmet’s hinting about his “medical breakthrough” stock… so let’s get to it. I did not watch or […]
I’ve got a few stocks to mention in the medical space this week — one to update that’s in my portfolio, one to confirm as a teaser pick (since folks keep asking) after several Gumshoe readers discussed it last week, and one to note as a teaser idea that’s being pushed pretty heavily (though the […]
Pinpoint Surgery
How about something on Stansberry’s latest – “Pinpoint Surgery” stock?
Before I get into the meat of today’s Friday File article, which plays off of one of the investing themes I feel most strongly about (the long-term growth potential of Africa), I should share a few housekeeping notes regarding my portfolio — I decided to sell Accuray (ARAY) and got stopped out of my position […]
I can be patient to the point of stubbornness, but Accuray (ARAY) has finally convinced me that they’re never going to become consistently profitable or to grow at the level that their business plan requires, so I’m closing my ARAY position today at a substantial loss. Accuray may well turn into a successful company someday, […]
This ad has been crashing in on Gumshoe beach in massive waves over the last week, so I thought it might be time to take a gander. It’s for the Xcelerated Profits report at Mt. Vernon Research — the last time I saw a similar ad it was from Karim Rahemtulla for this same report, […]
I haven’t written much about Rob Fannon and his Phase 1 Investor newsletter lately — this is the high end newsletter published by the folks at Stansberry and Associates, it’ll run you about $4,500 a year, and it’s largely focused on biotech companies. So is their advice worth more than the advice from less expensive […]
Well, this is something that doesn’t happen every day: we’ve got a repeat customer for one of the stocks we teased out in the past. This is a new teaser from Karim Rahemtulla for the Xcelerated Profits newsletter, but it happens to be for a stock that was previously recommended, in a poorly timed pre-earnings […]
This one comes in promising to find us the “next Intuitive Surgical” — and as an ISRG shareholder sitting on 100%+ gains, that really strikes a chord with me. Sounds like it’s worth a sleuthing moment or two. Intuitive Surgical, for those who don’t know, is the company that makes and sells the da Vinci, […]
Comments
No comments.